Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Core Scientific, Inc. filings document its high-density colocation data center business, digital asset mining activities, capital structure and public-company governance. Recent 8-K reports cover operating and financial results, Regulation FD disclosures, campus expansion updates, material agreements, debt financing and direct financial obligations.
The company’s filings also describe common stock and warrant securities listed on the Nasdaq Global Select Market, subsidiary financing arrangements, senior secured notes, credit agreement amendments, executive and accounting-officer governance matters, and annual proxy disclosures for shareholder voting, board matters and compensation programs.
Two Seas Capital and affiliates filed an amended Schedule 13D reporting beneficial ownership of 17,466,679 shares of Core Scientific, Inc. common stock, equal to about 5.5% of the outstanding shares. This total includes 313,646 shares issuable upon exercise of warrants and options to purchase 2,534,000 shares.
The filing explains that Core Scientific had 315,332,655 shares outstanding as of February 26, 2026, plus the 313,646 warrant shares. Two Seas Capital, its general partner and Sina Toussi share voting and investment power over securities held for various funds and accounts under investment management agreements.
The amendment also updates a Cooperation Agreement: on March 15, 2026, Two Seas Capital agreed to waive a requirement that Core Scientific appoint one independent director by that date, provided the company remains in compliance with the agreement and makes the appointment by May 30, 2026.
Core Scientific EVP and CFO James P. Nygaard Jr. reported a tax-related share disposition. On March 17, 2026, 92,725 shares of Common Stock were withheld at $16.42 per share to satisfy withholding tax obligations upon the vesting of restricted stock units, rather than sold in the open market.
After this withholding, Nygaard directly owns 928,928 shares of Core Scientific common stock. Footnotes indicate that a portion of his holdings also reflects earlier in-kind share distributions received for no cash consideration.
Core Scientific, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to add Exhibit 97.1, its Policy on Recoupment of Incentive Compensation, which was inadvertently omitted previously. The amendment does not change any financial or other disclosures in the original report.
The company’s common stock trades on the Nasdaq Global Select Market under the symbol CORZ, with warrants trading under CORZW and CORZZ. As of February 26, 2026, 315,332,655 shares of common stock were outstanding, and the non‑affiliate market value was approximately $4.25 billion based on a June 30, 2025 closing price of $17.07.
Valiant Capital Management reports passive stake in Core Scientific. Valiant Capital Management, L.P., Valiant Capital Management, LLC and Christopher R. Hansen jointly filed a Schedule 13G reporting beneficial ownership of 16,212,903 shares of Core Scientific, Inc. Common Stock, representing 5.1% of the class based on February 26, 2026.
The filing states the reporting persons have shared voting and shared dispositive power over the 16,212,903 shares. The Funds hold the shares for the benefit of their investors and no single Fund holds more than 5% of outstanding Common Stock.
Core Scientific director Eric Stanton Weiss bought 7,000 shares of common stock in an open-market transaction at an average price of $14.5285 per share on March 9, 2026. After this purchase, he directly holds 252,262 shares of Core Scientific common stock.
Core Scientific, Inc. entered into a senior secured term loan facility of $500.0 million with lenders arranged by Morgan Stanley Senior Funding, Inc. The 364-day facility bears interest at term SOFR plus 2.50%, and the company borrowed the full initial $500.0 million on March 5, 2026.
The credit agreement includes an accordion feature allowing Core Scientific to request up to an additional $500.0 million in commitments, for potential total commitments of $1.0 billion. Proceeds are earmarked for developing data center assets, including equipment, energy-related deposits and real estate, and to pay associated fees and expenses, but not to repay other debt or fund dividends.
The loans are guaranteed by certain wholly owned material domestic subsidiaries and secured by a first-priority lien on substantially all of their assets. Core Scientific may prepay at any time without penalty, but must also use 100% of specified asset sale, debt, insurance, equity raise and fee proceeds to reduce commitments or prepay loans, subject to customary exceptions.
Core Scientific, Inc. (CORZ) received an amended Schedule 13D/A from Two Seas Capital and affiliates reporting a 5.9% beneficial stake in its common stock. The group reports beneficial ownership of 18,716,679 shares, including 313,646 shares issuable upon exercise of warrants and options to purchase 2,034,000 shares of common stock.
The stake is held across the Strategic Fund, the Global Fund and separate Accounts, with aggregate purchase prices of $36,028,987.73, $146,749,421.80 and $7,180,487.49, respectively. Two Seas Capital has sole voting and investment power under investment management agreements, while the underlying funds and accounts and their investors participate economically through their partnership or investment interests.
Core Scientific, Inc. files its Annual Report describing a major shift from bitcoin-focused operations to high-density colocation data centers for AI and other high-performance computing workloads. As of December 31, 2025, it owned or leased ten U.S. data centers with about 1.4 GW of gross utility power capacity and 920 MW of total leasable customer power capacity.
The company has three segments: Colocation, Digital Asset Self-Mining, and Digital Asset Hosted Mining, with most 2025 revenue still from bitcoin mining but expected to tilt toward colocation in 2026 through large contracts with CoreWeave. Core Scientific highlights heavy capital needs, power-cost and power-availability risks, bitcoin price and network hash-rate pressure, climate and regulatory uncertainty, and dependence on a single colocation customer.
It discloses a material weakness in internal control over financial reporting and ongoing remediation efforts. As of June 30, 2025, the aggregate market value of non-affiliate common stock was approximately $4.25 billion, and as of February 26, 2026, 315,332,655 common shares were outstanding.
Core Scientific, Inc. filed an amended quarterly report for the period ended September 30, 2025 to restate prior financial statements and correct a material error in accounting for property, plant and equipment. Assets committed to demolition had been improperly capitalized instead of written down, overstating net property, plant and equipment by about $124.7 million and understating accumulated deficit by the same amount.
For the nine months ended September 30, 2025, revenue was $239.3 million, down from $415.7 million a year earlier, driven by lower digital asset self‑mining and hosted mining revenue, partly offset by growth in colocation revenue to $34.1 million. The company reported a net loss of $504.6 million versus $1.15 billion in the prior‑year period, with results heavily affected by a $363.4 million increase in the fair value of warrant and contingent value right liabilities.
As of September 30, 2025, cash and cash equivalents were $453.4 million, digital assets were $241.4 million, and there was a stockholders’ deficit of $1.25 billion, including warrant liabilities of $1.33 billion and convertible and other notes payable of $1.06 billion. Management identified a material weakness in internal control over financial reporting, concluding that internal control and disclosure controls were not effective for year‑ends 2024 and 2025 and the interim restated periods.
Core Scientific, Inc. filed an amended quarterly report to restate prior financial statements after identifying material errors in accounting for property, plant and equipment tied to converting bitcoin-mining facilities to high-performance computing colocation.
The company had improperly continued capitalizing assets committed to demolition instead of recording timely impairment charges. As of June 30, 2025, this restatement reduced property, plant and equipment by about $127.3 million and increased accumulated deficit by the same amount. Selling, general and administrative expense for the first half of 2025 rose by roughly $4.4 million, modestly increasing net loss, while revenue, cost of revenue and total net cash flows were unchanged, aside from a reclassification between investing and operating cash flows.
Core Scientific reported a six-month 2025 net loss of $360.5 million, heavily influenced by noncash fair-value losses on warrants and contingent value rights. At June 30, 2025, the company held $581.3 million of cash and cash equivalents and $172.8 million of bitcoin, against $3.04 billion of total liabilities and a stockholders’ deficit of $1.19 billion, including $1.32 billion of warrant liabilities and $1.06 billion of convertible and other notes payable, net.
Management concluded a material weakness exists in internal control over financial reporting related to this error, and determined that disclosure controls and procedures were not effective for 2024, 2025 and all affected interim periods. The amendment replaces key sections of the prior filing, including financial statements, management’s discussion and analysis, controls and procedures and risk factors. Core Scientific also highlights significant growth in its Colocation segment, backed by about $1.71 billion of capital-expenditure commitments to convert data centers for GPU-based workloads, most of which will be funded or reimbursed by its primary colocation customer.